Immunogenicity of hepatitis B surface antigen derived from the baculovirus expression vector system: a mouse potency study.
A standard mouse potency test was performed to evaluate the immunogenicity of recombinant hepatitis B surface antigen (HBsAg) produced in the baculovirus/insect cell expression system. Groups of NIH Swiss mice were immunized with serial four-fold amounts of either baculovirus-derived HBsAg adsorbed to aluminum sulfate or a commercially available yeast-derived recombinant HBsAg vaccine preparation. Results from these experiments showed that the effective dose of baculovirus- and yeast-derived HBsAg vaccine preparations necessary to seroconvert 50% of the animals were similar. The duration of the antibody response to HBsAg was studied in mice immunized with the highest doses of the two recombinant vaccine preparations 3 and 6 months after injection. No decrease in the anti-HBs response was observed 6 months after injection. No decrease in the anti-HBs response was observed 6 months after immunization with either of the two vaccine preparations. These results indicate that the baculovirus-derived recombinant HBsAg could serve as an alternative vaccine candidate for hepatitis B virus.
Attanasio
R
R
Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas 78228-0147.
Lanford
R E
RE
Dilley
D
D
Stunz
G W
GW
Notvall
L
L
Henderson
A B
AB
Kennedy
R C
RC
D000818:Animals; D016367:Baculoviridae / Q000235:genetics; D005260:Female; D005822:Genetic Vectors; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology*; D007114:Immunization; D051379:Mice; D014614:Vaccines, Synthetic / Q000032:analysis / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000032:analysis / Q000276:immunology
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines